<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851874</url>
  </required_header>
  <id_info>
    <org_study_id>Bariatric study</org_study_id>
    <nct_id>NCT03851874</nct_id>
  </id_info>
  <brief_title>Comparison of Gastric Bypass and Sleeve Gastrectomy in Metabolic and Cardiovascular Indices</brief_title>
  <official_title>A Comparative Study of the Effects of Roux en Y Gastric Bypass and Sleeve Gastrectomy on Postprandial Gut Hormone Responses, Glycemia and Lipid Profile, Weight Loss, and Indices of Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Morbidly obese patients undergoing either Roux en Y gastric bypass or sleeve gastrectomy were
      examined preoperatively, 3, 6, and 12 months after surgery. On each occasion, anthropometric
      data were collected, resting metabolic rate was measured, and the patients underwent a panel
      of cardiovascular examinations (heart rate variability, baroreflex sensitivity, heart
      ultrasound). Following that, they consumed a test meal and completed visual analog scales for
      the subjective assessment of hunger and fullness every 30 minutes for 3 hours. At the same
      time points, blood samples were collected for the consequent measurement of glucose, insulin,
      lipids, and gastrointestinal hormones.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in postprandial ghrelin responses</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in the cumulative postprandial response for ghrelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial GLP-1 responses</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in the cumulative postprandial response for GLP-1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in postprandial PYY responses</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in the cumulative postprandial response for PYY</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in weight (percentage of weight lost through each procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial glycemia</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in the cumulative postprandial response for glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial insulinemia</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in the cumulative postprandial response for insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in postprandial triglyceridemia</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Change in the cumulative postprandial response for triglycerides</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in baroreflex sensitivity</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Changes in baroreflex sensitivity</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in heart rate variability</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Changes in heart rate variability</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in aortic distensibility</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Changes in aortic distensibility</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Tei index</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Changes in echocardiographic Tei index</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Gastric bypass bariatric surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sleeve gastrectomy bariatric surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Bariatric surgery</description>
    <arm_group_label>Gastric bypass bariatric surgery</arm_group_label>
    <arm_group_label>Sleeve gastrectomy bariatric surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt;40 kg/m2

          -  Age between 18 and 65 years

          -  Proven failure to lose weight through non-surgical interventions

        Exclusion Criteria:

          -  Serious and life threatening comorbidities (renal, cardiac, liver failure, or
             malignancy)

          -  Patients' inability to adhere to postsurgical instructions

          -  Alcohol or other substance abuse

          -  Concurrent psychiatric illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Propaedeutic Medicine, NKUA</affiliation>
  </overall_official>
  <reference>
    <citation>Holst JJ, Madsbad S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis. 2016 Jul;12(6):1236-42. doi: 10.1016/j.soard.2016.02.033. Epub 2016 Mar 3. Review.</citation>
    <PMID>27313194</PMID>
  </reference>
  <reference>
    <citation>Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007 Nov-Dec;3(6):597-601. Epub 2007 Oct 23.</citation>
    <PMID>17936091</PMID>
  </reference>
  <reference>
    <citation>Dimitriadis GK, Randeva MS, Miras AD. Potential Hormone Mechanisms of Bariatric Surgery. Curr Obes Rep. 2017 Sep;6(3):253-265. doi: 10.1007/s13679-017-0276-5. Review.</citation>
    <PMID>28780756</PMID>
  </reference>
  <reference>
    <citation>Laferrère B, Swerdlow N, Bawa B, Arias S, Bose M, Oliván B, Teixeira J, McGinty J, Rother KI. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010 Aug;95(8):4072-6. doi: 10.1210/jc.2009-2767. Epub 2010 May 25.</citation>
    <PMID>20501690</PMID>
  </reference>
  <reference>
    <citation>Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014 Feb;24(2):241-52. doi: 10.1007/s11695-013-1066-0.</citation>
    <PMID>23996294</PMID>
  </reference>
  <reference>
    <citation>Farey JE, Preda TC, Fisher OM, Levert-Mignon AJ, Stewart RL, Karsten E, Herbert BR, Swarbrick MM, Lord RV. Effect of Laparoscopic Sleeve Gastrectomy on Fasting Gastrointestinal, Pancreatic, and Adipose-Derived Hormones and on Non-Esterified Fatty Acids. Obes Surg. 2017 Feb;27(2):399-407. doi: 10.1007/s11695-016-2302-1.</citation>
    <PMID>27465935</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Alexandros Kokkinos</investigator_full_name>
    <investigator_title>Associate Professor in Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Bariatric surgery, gut peptides, weight loss, glycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

